SG138623A1 - Use of ppr delta agonists for treating demyelinating diseases - Google Patents

Use of ppr delta agonists for treating demyelinating diseases

Info

Publication number
SG138623A1
SG138623A1 SG200800123-2A SG2008001232A SG138623A1 SG 138623 A1 SG138623 A1 SG 138623A1 SG 2008001232 A SG2008001232 A SG 2008001232A SG 138623 A1 SG138623 A1 SG 138623A1
Authority
SG
Singapore
Prior art keywords
ppr
demyelinating diseases
delta agonists
treating demyelinating
treating
Prior art date
Application number
SG200800123-2A
Other languages
English (en)
Inventor
Karen Chandross
Jean Merrill
Anne Minnich
Lan Lee
Olga Khorkova
Yun Liu
Original Assignee
Aventis Pharmaceuticals Inc Us
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc Us filed Critical Aventis Pharmaceuticals Inc Us
Publication of SG138623A1 publication Critical patent/SG138623A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG200800123-2A 2004-04-01 2005-03-29 Use of ppr delta agonists for treating demyelinating diseases SG138623A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55853304P 2004-04-01 2004-04-01

Publications (1)

Publication Number Publication Date
SG138623A1 true SG138623A1 (en) 2008-01-28

Family

ID=34977094

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200800123-2A SG138623A1 (en) 2004-04-01 2005-03-29 Use of ppr delta agonists for treating demyelinating diseases

Country Status (16)

Country Link
US (1) US20070149580A1 (fr)
EP (1) EP1737440A2 (fr)
JP (1) JP2007530703A (fr)
KR (1) KR20060134191A (fr)
CN (1) CN1950077A (fr)
AU (1) AU2005231358A1 (fr)
BR (1) BRPI0509540A (fr)
CA (1) CA2561159A1 (fr)
IL (1) IL178165A0 (fr)
MA (1) MA28561B1 (fr)
MX (1) MXPA06011218A (fr)
NO (1) NO20064985L (fr)
RU (1) RU2006138495A (fr)
SG (1) SG138623A1 (fr)
WO (1) WO2005097098A2 (fr)
ZA (1) ZA200607850B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968723B2 (en) 2004-05-05 2011-06-28 High Point Pharmaceuticals, Llc Compounds, their preparation and use
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
EP2298742B1 (fr) 2005-06-30 2014-01-08 High Point Pharmaceuticals, LLC acides phénoxyacétiques en tant qu'activateurs PPAR delta
JP5186217B2 (ja) * 2005-11-28 2013-04-17 千寿製薬株式会社 Ｐｐａｒアゴニスト含有医薬
BRPI0620468A2 (pt) 2005-12-22 2011-11-08 Transtech Pharma Inc ácidos fenóxi acéticos como ativadores de ppar delta
CA2645719A1 (fr) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Nouveaux composes, leur preparation et utilisation
MX2010013264A (es) 2008-06-09 2011-02-25 Sanofi Aventis Sulfonamidas n-heterociclicas aneladas con grupo de cabeza de oxadiazolona, procesos para su preparacion y su uso como sustancias farmaceuticas.
WO2010000353A1 (fr) 2008-06-09 2010-01-07 Sanofi-Aventis Sulfonamides comprenant un hétérocycle et un groupe de tête oxadiazolone, procédés pour les préparer et leur utilisation comme produits pharmaceutiques
CA2774999A1 (fr) 2009-09-30 2011-04-07 President And Fellows Of Harvard College Procedes de modulation de l'autophagie par la modulation de produits geniques renforcant l'autophagie
AU2010340238B2 (en) 2009-12-17 2016-07-21 Sanofi Animal model expressing luciferase under control of the myelin basic protein promoter (MBP-luci) and use of the model for bioluminescence in vivo imaging
EP3502236B1 (fr) * 2011-02-18 2023-08-23 The Scripps Research Institute Différenciation dirigée de cellules précurseurs d'oligodendrocytes vers un destin de cellules myélinisantes
WO2015035171A1 (fr) 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Utilisation d'un agoniste de ppar-delta pour le traitement d'une amyotrophie
WO2023147309A1 (fr) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Utilisation d'agonistes ppar-delta dans le traitement d'une maladie

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028149A1 (fr) * 1996-02-02 1997-08-07 Merck & Co., Inc. Procede pour augmenter les niveaux de cholesterol hdl
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
AU2001288271A1 (en) * 2000-08-17 2002-02-25 Harrihar A. Pershadsingh Methods for treating inflammatory diseases
GB0024362D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
GB0024361D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
WO2004082621A2 (fr) * 2003-03-15 2004-09-30 Bethesda Pharmaceuticals, Inc. Nouveaux agonistes ppar, compositions pharmaceutiques et leurs utilisations
EP1637161A4 (fr) * 2003-04-22 2007-06-27 Astellas Pharma Inc REMEDE CONTRE DES MALADIES CEREBRALES NEURODEGENERATIVES UTILISANT UN AGONISTE DES PPAR [delta]

Also Published As

Publication number Publication date
AU2005231358A1 (en) 2005-10-20
NO20064985L (no) 2006-10-31
ZA200607850B (en) 2008-10-29
MA28561B1 (fr) 2007-04-03
KR20060134191A (ko) 2006-12-27
MXPA06011218A (es) 2007-01-16
US20070149580A1 (en) 2007-06-28
RU2006138495A (ru) 2008-05-10
WO2005097098A3 (fr) 2005-12-22
WO2005097098A2 (fr) 2005-10-20
EP1737440A2 (fr) 2007-01-03
IL178165A0 (en) 2008-03-20
BRPI0509540A (pt) 2007-09-18
JP2007530703A (ja) 2007-11-01
CA2561159A1 (fr) 2005-10-20
CN1950077A (zh) 2007-04-18

Similar Documents

Publication Publication Date Title
IL178165A0 (en) Use of ppr delta agonists for treating demyelinating diseases
EP2063897A4 (fr) Inhibiteurs de kinases utiles pour le traitement de maladies prolifératives
EP2063896A4 (fr) Inhibiteurs de la kinase utiles dans le traitement de maladies prolifératives
HK1139036A1 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
PL2001892T3 (pl) Imidazolotiazolowe związki do leczenia chorób proliferacyjnych
ZA200801253B (en) Novel use of peptide compounds for treating muscle pain
ATE542823T1 (de) 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
IL227841A0 (en) Dihydropyridinones for the treatment of cancer
HK1171736A1 (en) Substituted acids for the treatment of respiratory diseases
IL176028A0 (en) Compounds for treatment of cell proliferative diseases
IL173386A0 (en) Use of adcc-optimized antibodies for treating weak patients
EP1737482A4 (fr) Compositions et methodes de traitement de maladies
EP2063889A4 (fr) Inhibiteurs de la spiropipéridine bêta-sécrétase pour le traitement de la maladie d'alzheimer
EP2019649A4 (fr) Compositions et méthodes pour traiter ou prévenir des maladies de voies du corps
IL184934A0 (en) 4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases
IL179210A0 (en) Heterocyclic derivatives for treatment of hyperlipidemia and related diseases
EP1750513A4 (fr) Utilisation de ligands gpcr54 pour le traitement de l'infertilite
EP1867640A4 (fr) Agent pour le traitement d'une tumeur solide
EP1709155A4 (fr) Composes et compositions destines au traitement de maladies dysplasiques, et leurs methodes d'utilisation
EP1701735A4 (fr) Procedes et compositions a utiliser pour le traitement des diabetes
HK1090377A1 (en) Process for the preparation of tubulin inhibitors
ZA200704971B (en) Pyrid-2-ones useful as inhibitors of Tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases
PT1742937E (pt) Derivados de pirrolopirimidina úteis para o tratamento de doenças proliferativas
IL188894A0 (en) Compounds for treatment of lipase-mediated diseases
ZA200606780B (en) Compounds for the treatment of diseases